

Addressing issues for ATMP logistics


Mark Briggs

June 2020

Funded by










Background



What we have done

Workshop with multiple stakeholders – confirmed guidance needed on first/last 100m Test deliveries across multiple sites in MW-ATTC and lessons learned Gap analysis carried out by NA-ATTC Multiple follow up interactions across NHS



Issues faced within hospitals

- Most hospitals have grown organically over time, no two hospitals are alike (challenging to give standard advice)
- Cell/gene therapies are still new to most hospitals lack of experience or established teams
- Cell therapy pathway is long and complex, especially so for autologous therapies
- Depending on the treatment there are multiple treatment pathways within a hospital
- Large team involved in safe delivery, multiple disciplines involved
- Pharmacy needs to have oversight of ATMP at receipt from courier to delivery to patient
- Infrastructure not in place for storage on site everywhere meaning ATMPs may need to be stored offsite (e.g. NHS-BT). Wi-Fi blackspots etc...space and flexibility of pharmacy facilities
- Stem cell labs required for cryogenic (-150°C) storage not usually involved in storing medicines inexperienced with the regulatory framework surrounding medicines

Coordinated by



Infrastructure

Common issues	Potential solutions
No pharmacy storage for ATMPs	Pharmacy working group (PWG) is developing standard guidance for working with external groups to store ATMPs NHS-BT providing off site storage for some hospitals Footprint for shipping units development of agreements
Maintaining temperature during final transit to administration	Use dry ice or vapour phase cryogenic container to transport ATMP within hospital. Agreement on responsibilities for equipment
Institutions develop a system that is only suitable for a small number of treatments	Institutions need to consider the viability of their internal receipt, storage and dispensing routes for in ever increasing number of treatments
Wi-Fi blackspots	Test runs to identify issues and hospitals
Storage requirements prior to shipping offsite	Commonality is being identified by SAMPLE project

Coordinated by

Cell and Gene Therapy

.

Advanced Therapy Treatment Centres

Governance

Common issues	Potential solutions
Pharmacy need oversight of ATMP storage when not held in pharmacy	<u>PWG</u> are developing standard guidance for working with external groups to store ATMPs
Lack of governance in place for ATMPs	ATTCs sharing best practice on governance structure with other hospitals Institutional readiness development across ATTCs GM and safety committees that are comfortable with procedures and products

Coordinated by





Team

Common issues	Potential solutions
Provision of oversight for pharmacy without holding medicines in their facility	Pharmacy need to develop service level agreement or technical agreement with whichever party is storing treatment.
Stem cell labs inexperienced with the regulatory framework surrounding medicines	Pharmacy can educate teams on the requirements, establish governance for advanced therapies. Very clear pharmacy manuals from sponsors / vendors
Pharmacy are unfamiliar with Stem cell labs processes and storage devices along with hazards, limitations and monitoring	Stem cell lab can educate pharmacy on their facilities and procedures
Poor communication leading to an increased risk of lost products or delays in treatment	There is a need for well defined communication channels. Multi-disciplinary team from hospital door to patient established with regular update meetings being held to raise and resolve issues arising develop coordinating teams and roles across departments and disciplines Communication to patient as needed post administration issues starts with prescription
Lack of coordination across interlinked elements of the process	Well defined team and communication channels across the disciplines



Advanced Therapy Treatment Centres

Well defined pathways

Common issues	Potential solutions
Lack of clarity of delivery point preventing the courier finding the delivery destination	Clear instructions given to manufacturer and courier companies. Walk through the path with delivery companies from arrival to hand over point can have multiple pharmacies within facilities, (follow yellow lines) couriers commonly have subcontracted drivers, can't assume same driver day to day
Lack of actual name to deliver to due to uncertainty with shift patterns	Deliver to job role or agreed backup team. Have clear contact details and escalation contact points Define delivery times with vendors, clear communication plans


Coordinated by CATAPULS Cell and Gene Therapy


. . ..

.



Pathway from courier to patient







Advanced Therapy Treatment Centres

Next steps

Produce guidance paper for hospitals to set up or improve their internal logistics

PWG producing guidance for working with stem cell labs and blood services

Describe ATMP coordinator role to help solve communication issues

Sharing of governance procedures across hospitals

Input sought

- What are your pain points, are we covering them based on your experience?
- What examples of good or bad practice have you seen?
- Please share your thoughts (<u>lan.Hollingsworth@ct.catapult.org.uk</u>)

Coordinated by